Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

Adam Ajina*, John Maher

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

16 Citations (Scopus)


For patients with advanced hematological malignancies the therapeutic landscape has been transformed by the emergence of adoptive cell transfer utilizing autologous chimeric antigen receptor (CAR)-redirected T-cells. However, solid tumors have proved far more resistant to this approach. Here, we summarize the numerous challenges faced by CAR T-cells designed to target solid tumors, highlighting, in particular, issues related to impaired trafficking, expansion, and persistence. In parallel, we draw attention to exciting developments in the burgeoning field of oncolytic virotherapy and posit strategies for the synergistic combination of oncolytic viruses with CAR T-cells to improve outcomes for patients with advanced solid tumors.

Original languageEnglish
Title of host publicationProgress in Molecular Biology and Translational Science
EditorsDavid B. Teplow
PublisherElsevier B.V.
Number of pages76
ISBN (Print)9780128165751
Publication statusPublished - 1 Jan 2019

Publication series

NameProgress in Molecular Biology and Translational Science
ISSN (Print)1877-1173
ISSN (Electronic)1878-0814


  • Adoptive cell transfer
  • CAR T-cell
  • Chimeric antigen receptor
  • Combination strategies
  • Oncolytic virus
  • Solid tumors
  • Synergism

Cite this